Latest Content

A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.

Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.

A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that treatment lowers risk.

A review maps psoriasis's 3-stage path to psoriatic arthritis and tools to catch it before joint damage.

The study authors indicated that future investigations could further facilitate clinical decision-making regarding these regimens’ effectiveness.

AHIP's Jeanette Thornton details health care's prior authorization commitments as a 2027 real-time approval target approaches.

Pulmonary experts detail bronchiectasis care gaps, multidisciplinary strategies, and steps toward Care Center Network designation and standardized care.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.

The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy.